Novo-Backed Respiratory Drugmaker Avalyn Pharma Files for US IPO

Avalyn Pharma Inc., a biopharma company developing inhaled treatments for respiratory diseases, filed for a US initial public offering.

The Boston-based company’s pipeline is focused on treating pulmonary fibrosis, a disease with a median survival rate of three to five years, according to its filing Wednesday with the US Securities and Exchange Commission.